Raytheon awarded $71 million in Navy contracts for missile systems
Elevance Health, Inc., formerly known as Anthem, Inc., has reaffirmed its earnings guidance for the full year 2025. The company expects to report earnings of $30.40 to $31.10 per diluted share, which includes approximately $3.75 per diluted share of net unfavorable items. Excluding these items, the adjusted earnings are projected to be between $34.15 and $34.85 per diluted share. According to InvestingPro data, the healthcare giant, currently valued at $93.24 billion, trades at a P/E ratio of 15.97x, suggesting a premium valuation relative to its near-term earnings growth potential.
The Indianapolis-based health insurance provider also anticipates that the total medical enrollment by the end of 2025 will align with previous forecasts shared in the Fourth Quarter 2024 Earnings Release on January 23, 2025. This includes expectations for Medicare Advantage membership to range between 2.2 million and 2.25 million members. The company’s strong market position is reflected in its "GREAT" financial health score on InvestingPro, supported by consistent dividend growth for 14 consecutive years and stable revenue of $176.81 billion in the last twelve months.
These statements were part of a regulatory disclosure filed today with the Securities and Exchange Commission (SEC), where company officers indicated that they would be discussing these projections with investors over the coming weeks. With the next earnings report due on April 16, 2025, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports, which transform complex financial data into actionable intelligence.
Elevance Health operates under the umbrella of hospital and medical service plans, with a fiscal year ending on December 31. The company, which trades on the New York Stock Exchange under the ticker (NYSE:ELV), has highlighted that the information provided in the SEC filing is not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and should not be incorporated by reference into any future filings under the Securities Act of 1933.
The forward-looking statements contained in the document are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These include changes in healthcare costs, enrollment trends, regulatory changes, and other factors as detailed in the company’s filings with the SEC.
Investors are advised to review these factors carefully, as they can significantly impact the company’s financial performance and results. The information in this article is based on a press release statement from Elevance Health, Inc.
In other recent news, Elevance Health reported fourth-quarter results for fiscal year 2024 that aligned with consensus expectations, posting adjusted earnings per share (EPS) of $3.84 and revenues of $45.0 billion. Bernstein analysts responded by raising Elevance’s stock price target to $511, citing a stable outlook and maintaining an Outperform rating. Meanwhile, JPMorgan adjusted its financial outlook for Elevance, lowering the price target to $479 due to a mixed view of the company’s future performance, although it still maintains an Overweight rating. The firm’s analysis pointed to challenges in Elevance’s Medicaid segment but noted potential improvements in margins from state rate updates.
Additionally, Cantor Fitzgerald reaffirmed an Overweight rating with a price target of $485, highlighting Elevance’s exposure to Medicaid policies and its significant revenue from Medicaid expansion lives. The firm noted that changes in Medicaid funding could impact Elevance’s financial stability. In broader industry news, the healthcare sector, including Elevance Health, experienced a downturn following a Department of Justice investigation into UnitedHealth Group (NYSE:UNH)’s Medicare billing practices. This development has raised concerns about potential regulatory scrutiny affecting other companies involved in Medicare Advantage plans.
On a positive note, healthcare stocks, including Elevance Health, saw an increase following President Trump’s supportive comments on social security, Medicare, and Medicaid, which investors perceived as favorable for the stability of these programs. The market’s reaction underscores the importance of federal support for the sustainability of social programs and the companies that administer them. These recent developments reflect the dynamic landscape in which Elevance Health operates, with both challenges and opportunities influencing investor sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.